G protein-coupled receptors: a count of 1001 conformations

Fundamental & Clinical Pharmacology
G Vauquelin, I Van Liefde


G protein-coupled receptors (GPCRs) were initially regarded to adopt an inactive and an active conformation and to activate a single type of G protein. Studies with recombinant cell systems have led to a more complex picture. First, GPCRs can activate distinct G protein species. Second, GPCR multistate models have been invoked to explain their complex behaviour in the presence of agonists, antagonists and other binding partners. The occurrence of intermediate receptor conformational states during GPCR activation and antagonist binding is suggested by fluorescence measurements and studies with constitutively active receptor mutants and insurmountable antagonists. Different agonists may trigger distinct effector pathways through a single receptor by dictating its preference for certain G proteins (i.e. 'agonist trafficking'). Structural modification and exogenous and endogenous (e.g. other cellular proteins, lipids) allosteric modulators also affect ligand-GPCR interaction and receptor activation. These new developments in GPCR research could lead to the development of more selective therapeutic drugs.


Jun 20, 1990·Journal of Molecular Biology·R HendersonK H Downing
Jul 1, 1995·Trends in Pharmacological Sciences·T Kenakin
Jan 1, 1995·Journal of Cardiovascular Pharmacology·S MochizukiA Tomiyama
Jan 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·K L LaugwitzG Schultz
Nov 14, 1997·Trends in Pharmacological Sciences·P LeffK McKechnie
Jul 3, 1998·European Journal of Pharmacology·D LebesgueJ Hoebeke
Jul 11, 1998·The Journal of Biological Chemistry·U Gether, B K Kobilka
Jan 15, 1999·Pharmacology & Therapeutics·J Wess
Jul 8, 1999·European Journal of Pharmacology·F L FierensG Vauquelin
Aug 12, 1999·European Journal of Pharmacology·E C HulmeC A Curtis
Nov 5, 1999·Biochimica Et Biophysica Acta·D R Flower
Jun 8, 2000·The Journal of Biological Chemistry·S R GeorgeB F O'Dowd
Aug 5, 2000·Science·K PalczewskiM Miyano
Dec 21, 2000·Trends in Pharmacological Sciences·C JuanedaR Quirion
Jul 19, 2001·The Journal of Biological Chemistry·T PalancheJ L Galzi
Jul 20, 2001·Trends in Pharmacological Sciences·G VauquelinP Vanderheyden
Oct 5, 2001·Trends in Pharmacological Sciences·G Milligan, J H White
Feb 16, 2002·The Journal of Biological Chemistry·John J MalleeStefanie A Kane
Mar 8, 2002·Cellular Signalling·Eun Mi Hur, Kyong Tai Kim
Mar 28, 2002·Pharmacology & Therapeutics·C D RiosL A Devi
Apr 23, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·P M VanderheydenG Vauquelin

❮ Previous
Next ❯


Nov 15, 2006·Journal of Computer-aided Molecular Design·Masha Y NivHarel Weinstein
Aug 27, 2009·Proceedings of the National Academy of Sciences of the United States of America·Ilya A BalabinDavid N Beratan
Aug 31, 2006·The Journal of Experimental Medicine·Jennifer M BurnsThomas J Schall
May 11, 2011·Future Medicinal Chemistry·Christofer S Tautermann
Mar 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Noriko MakitaTaroh Iiri
Nov 30, 2005·Proceedings of the National Academy of Sciences of the United States of America·Thomas D PerroudRichard N Zare
Nov 23, 2005·Expert Opinion on Therapeutic Targets·Chih-Min Tang, Paul A Insel
Jul 16, 2008·Molecular and Cellular Endocrinology·I Van Liefde, G Vauquelin
May 27, 2008·Pharmacology & Therapeutics·Alberto J Kaumann, Peter Molenaar
Apr 26, 2008·Biochemical Pharmacology·Ann PackeuGeorges Vauquelin
Oct 8, 2011·Immunology·Laura D BennettNathalie Signoret
Dec 18, 2009·Fundamental & Clinical Pharmacology·Ann PackeuGeorges Vauquelin
Nov 25, 2006·Pharmacology & Therapeutics·Stanislav Engel, Marvin C Gershengorn
Sep 28, 2014·General and Comparative Endocrinology·Jeremy W ProkopAmy Milsted
Sep 11, 2013·Biochimica Et Biophysica Acta·Irina S Moreira
Sep 13, 2011·Journal of Molecular Biology·Jennifer L Miller, Christopher G Tate
Nov 30, 2006·Journal of Peptide Science : an Official Publication of the European Peptide Society·Patricia Cano-SanchezFred Naider
Apr 25, 2007·The Journal of Biological Chemistry·Zhi-Liang LuRobert P Millar
Nov 17, 2009·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Taroh Iiri, Noriko Makita
May 31, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Metehan IlterOzge Sensoy
Mar 21, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Emeline L MailletJean-Luc Galzi
May 10, 2015·Journal of Leukocyte Biology·James M FoxNathalie Signoret
Mar 23, 2006·The Journal of Biological Chemistry·Stanislav EngelMarvin C Gershengorn
Jul 20, 2007·Biochemical Society Transactions·B Chini, M Manning
May 11, 2019·Science·Tony WarneChristopher G Tate
May 4, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·S Courtney FraschDonna L Bratton
Apr 5, 2018·The Journal of Physical Chemistry. B·Yuta KajiwaraMasahiro Kinoshita
Jan 20, 2021·The Journal of Physical Chemistry. B·Aysima HacisuleymanBurak Erman

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.